Our passion for innovation

Ncardia believes that stem cell technology fast-tracks the delivery of better medicines to patients by improving the drug discovery process. We develop, produce and commercialize highly-predictive human cellular (disease) assay systems for safety and efficacy testing aiming to accelerate and improve drug candidate selection, reduce costs and ultimately increase drug discovery and development efficiency.


hiPSC-derived Cardiac and Neural products

The cardiac product portfolio includes hiPSC-derived cardiomyocytes, frozen or in ready-to-use CardioPlateTM assay plates. The neural cell product portfolio contains the pan-neuronal cells CNS.4U®, peripheral neurons Peri.4U®, and astrocytes Astro.4U®.


Industry-leading iPSC Services

Ncardia provides its customers with a broad portfolio of cardiovascular and neural iPSC services for safety and efficacy testing and analysis. The safety services are pre-configured service packages based on electrophysiology, biochemistry and contraction assay technology for predictive safety pharmacology and toxicology testing. Our DiscoverHIT platform provides a flexible solution for bringing hiPSC disease models to drug discovery campaigns.


We are ready to help

Ncardia is committed to delivering to its clients working assay solutions, through in-house assay development and customized support. By combining our deep portfolio of differentiated cardiac and neuronal iPSC cell products with our well-equipped laboratories, we provide scientists with top quality support for almost every application. The company has freely available application scientists knowledgeable in areas including but not limited to electrophysiology-, biochemistry- and contraction-based assays for predictive safety pharmacology and toxicology testing. Do not hesitate to talk to our experts today!